The group's principal activity is to develop therapeutics, for human diseases and disorders. The group is focused on the dermatology marketplace, which is characterized by a large patient population that is served by a relatively small number of treating physicians. The two pharmaceutical products of the group are, olux foam & luxiq(R) foam. These two dermatology products have clinically proven therapeutic advantages for the treatment of dermatoses in a novel formulation. The group sells their product directly to wholesale distributors and also provide quality customer service to dermatologists through their experienced sales and marketing professionals.
